BioInvent International AB (OSTO:BINV)
kr 43.2 -0.05 (-0.12%) Market Cap: 2.84 Bil Enterprise Value: 1.80 Bil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

Q3 2022 BioInvent International AB Earnings Call Transcript

Oct 27, 2022 / 12:00PM GMT
Release Date Price: kr40.3 (-3.24%)
Martin Welschof;publ;CEO
BioInvent International AB

()-

Thank you very much and welcome, everybody, to our call, and I will jump right into the presentation.

So on slide 3, we have summarized the events during the third quarter and we have actually quite some things. So we did successfully a direct share issue of approximately SEK300 million. We added two new members to the Board, Natalie Berner of Redmile and Nanna Lüneborg from Forbion. They were elected as new Board members of BioInvent.

And then we received also an upfront payment of USD25 million from the option and license agreement with Exelixis.

Then also we pushed ahead with our clinical programs. So we have the first patient enrolled in the Phase 1/2a evaluating our second anti-Fc gamma BI-1607 for the treatment of HER2 positive solid tumors.

We also completed, as planned, the dose escalation in the Phase 1/2a trial of BI-1808, which is our first and lead antibody against TNF receptor protein and we test this in advanced malignancies.

And then also we're very happy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot